Barclays Lowers Humana (NYSE:HUM) Price Target to $268.00

Humana (NYSE:HUM - Free Report) had its target price cut by Barclays from $273.00 to $268.00 in a research report report published on Thursday,Benzinga reports. They currently have an equal weight rating on the insurance provider's stock.

Other equities analysts have also issued reports about the stock. Raymond James upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price on the stock in a research report on Thursday, May 1st. Morgan Stanley lowered their price objective on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Guggenheim assumed coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price objective on the stock. Truist Financial decreased their target price on shares of Humana from $325.00 to $305.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Sixteen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Humana presently has an average rating of "Hold" and a consensus target price of $284.24.

Humana Stock Up 1.3%

Shares of NYSE:HUM traded up $2.94 during trading on Thursday, hitting $234.68. 1,419,440 shares of the company were exchanged, compared to its average volume of 1,790,410. The firm's 50 day moving average price is $251.76 and its 200-day moving average price is $263.78. Humana has a 12-month low of $212.45 and a 12-month high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $28.32 billion, a P/E ratio of 23.59, a PEG ratio of 2.05 and a beta of 0.43.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. Humana's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the business earned $7.23 EPS. On average, research analysts predict that Humana will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.51%. Humana's payout ratio is 25.04%.

Institutional Trading of Humana

Large investors have recently modified their holdings of the business. Revolve Wealth Partners LLC purchased a new position in shares of Humana during the fourth quarter valued at approximately $202,000. Apollon Wealth Management LLC increased its holdings in Humana by 6.0% in the 4th quarter. Apollon Wealth Management LLC now owns 2,983 shares of the insurance provider's stock valued at $757,000 after purchasing an additional 168 shares in the last quarter. Savant Capital LLC raised its holdings in shares of Humana by 1.9% during the 4th quarter. Savant Capital LLC now owns 3,327 shares of the insurance provider's stock valued at $844,000 after buying an additional 63 shares during the period. Van ECK Associates Corp increased its stake in Humana by 151.4% during the 4th quarter. Van ECK Associates Corp now owns 3,366 shares of the insurance provider's stock worth $854,000 after buying an additional 2,027 shares during the period. Finally, Vontobel Holding Ltd. lifted its stake in shares of Humana by 36.5% in the fourth quarter. Vontobel Holding Ltd. now owns 5,365 shares of the insurance provider's stock worth $1,361,000 after acquiring an additional 1,434 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.